These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28743299)

  • 21. Methods and challenges in measuring the impact of national pneumococcal and rotavirus vaccine introduction on morbidity and mortality in Malawi.
    Bar-Zeev N; Kapanda L; King C; Beard J; Phiri T; Mvula H; Crampin AC; Mwansambo C; Costello A; Parashar U; Tate JE; Verani JR; Whitney CG; Heyderman RS; Cunliffe NA; French N;
    Vaccine; 2015 May; 33(23):2637-45. PubMed ID: 25917672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study.
    Simpson CR; Lone NI; Kavanagh K; Englishby T; Robertson C; McMenamin J; Wissman BV; Vasileiou E; Butler CC; Ritchie LD; Gunson R; Schwarze J; Sheikh A
    Health Technol Assess; 2020 Dec; 24(67):1-66. PubMed ID: 33256892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cost-effectiveness of a modestly effective HIV vaccine in the United States.
    Long EF; Owens DK
    Vaccine; 2011 Aug; 29(36):6113-24. PubMed ID: 21510996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
    Brydak L; Roiz J; Faivre P; Reygrobellet C
    Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. More to Offer Than Direct Clinical Benefit: FDA's Vaccine Licensure Process Ignores Population Health and Social Determinants of Disease.
    Jones M; Jetelina KK
    Am J Epidemiol; 2024 Jan; 193(1):1-5. PubMed ID: 37527824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].
    Hernández-Ávila M; Lazcano-Ponce E; Hernández-Ávila JE; Alpuche-Aranda CM; Rodríguez-López MH; García-García L; Madrid-Marina V; López Gatell-Ramírez H; Lanz-Mendoza H; Martínez-Barnetche J; Díaz-Ortega JL; Ángeles-Llerenas A; Barrientos-Gutiérrez T; Bautista-Arredondo S; Santos-Preciado JI
    Salud Publica Mex; 2016; 58(1):71-83. PubMed ID: 26879510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly.
    Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M
    Vaccine; 2019 Apr; 37(15):2051-2056. PubMed ID: 30871927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A population based study comparing changes in rotavirus burden on the Island of Ireland between a highly vaccinated population and an unvaccinated population.
    Armstrong G; Gallagher N; Cabrey P; Graham AM; McKeown PJ; Jackson S; Dallat M; Smithson RD
    Vaccine; 2016 Sep; 34(39):4718-4723. PubMed ID: 27527819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leveraging contact network structure in the design of cluster randomized trials.
    Harling G; Wang R; Onnela JP; De Gruttola V
    Clin Trials; 2017 Feb; 14(1):37-47. PubMed ID: 27798376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
    Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
    PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.
    Patel MM; Parashar UD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S291-9. PubMed ID: 19817612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On measures and models for the effectiveness of vaccines and vaccination programmes.
    Greenland S; Frerichs RR
    Int J Epidemiol; 1988 Jun; 17(2):456-63. PubMed ID: 3403141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden.
    Kim SY; Sweet S; Chang J; Goldie SJ
    BMC Infect Dis; 2011 Jun; 11():174. PubMed ID: 21679420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.
    Valencia-Mendoza A; Bertozzi SM; Gutierrez JP; Itzler R
    BMC Infect Dis; 2008 Jul; 8():103. PubMed ID: 18664280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.
    Lopalco PL; DeStefano F
    Vaccine; 2015 Mar; 33(13):1541-8. PubMed ID: 25444788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Needle size for vaccination procedures in children and adolescents.
    Beirne PV; Hennessy S; Cadogan SL; Shiely F; Fitzgerald T; MacLeod F
    Cochrane Database Syst Rev; 2015 Jun; (6):CD010720. PubMed ID: 26086647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of typhoid fever transmission dynamic models and economic evaluations of vaccination.
    Watson CH; Edmunds WJ
    Vaccine; 2015 Jun; 33 Suppl 3(Suppl 3):C42-54. PubMed ID: 25921288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.